Dataset Information

Interval Between Cancer Diagnosis and Radiotherapy - An Independent Prognostic Factor of Survival in Patients Irradiated for Bone Metastases from Kidney Cancer.

ABSTRACT: BACKGROUND/AIM:Cancer patients with metastatic disease require personalized treatment regimens. This study was performed to identify prognostic factors for overall survival (OS) following irradiation of bone metastases from kidney cancer. PATIENTS AND METHODS:Data of 29 patients irradiated for bone metastases from kidney cancer were retrospectively evaluated. Ten factors were analyzed, including age, gender, performance score, interval from diagnosis of kidney cancer until radiotherapy for bone metastases, visceral metastases, other bone metastases, metastatic sites, number of irradiated sites, surgery of irradiated sites and systemic treatment prior to radiotherapy. RESULTS:Using univariate analyses, a longer interval from diagnosis of kidney cancer radiotherapy was associated with better OS (p=0.012). Using Cox regression analysis, this factor remained significant (risk ratio=3.54, p=0.012). CONCLUSION:The interval from diagnosis of kidney cancer until radiotherapy is an independent prognostic factor associated with OS following irradiation of bone metastases from kidney cancer. This type of data can help personalize radiation programs.

SUBMITTER: Rades D

PROVIDER: S-EPMC7157884 | biostudies-literature | 2020 Mar-Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Interval Between Cancer Diagnosis and Radiotherapy - An Independent Prognostic Factor of Survival in Patients Irradiated for Bone Metastases from Kidney Cancer.

Rades Dirk D Haus Rapha R Janssen Stefan S Schild Steven E SE

In vivo (Athens, Greece) 20200301 2

<h4>Background/aim</h4>Cancer patients with metastatic disease require personalized treatment regimens. This study was performed to identify prognostic factors for overall survival (OS) following irradiation of bone metastases from kidney cancer.<h4>Patients and methods</h4>Data of 29 patients irradiated for bone metastases from kidney cancer were retrospectively evaluated. Ten factors were analyzed, including age, gender, performance score, interval from diagnosis of kidney cancer until radioth ...[more]

PMID: 32111782

Similar Datasets

Project description:INTRODUCTION:Population-based data on the incidence and prognosis of bone metastases at diagnosis of breast cancer are currently limited. Hence, we conducted this study to analyze the incidence proportions and prognostic factors of patients with breast cancer and bone metastases at the time of cancer diagnosis. MATERIALS AND METHODS:Patients with primary invasive breast cancer and bone metastases at initial diagnosis between 2010 and 2014 were identified using the Surveillance, Epidemiology, and End Results (SEER) dataset and Fudan University Shanghai Cancer Center (FUSCC) cohort. Multivariable logistic regression was performed to identify predictors of the presence of bone metastases at diagnosis. Univariate and multivariate analyses were performed to determine the effects of each variable on survival. RESULTS:Of 229, 195 patients from SEER database included in the analysis, 8295 patients had bone metastases at initial diagnosis, reflecting 3.6% of the entire study population, and 65.1% of the subset with metastatic disease to any distant site. Patients with hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative represented the highest incidence proportions among patients with metastatic disease (73.9%). Among entire cohort, multivariable logistic regression identified eight factors as predictors of the presence of bone metastases at diagnosis. Median OS for the patients with bone metastases in SEER and FUSCC cohorts was 30.0 and 68.2 months, respectively. Patients with HR-positive HER2-positive subtype had the longest median OS, and patients with triple-negative subtype showed the shortest median OS. Multivariable Cox model in SEER cohort confirmed age, histology, grade, tumor subtype, extraosseous metastatic sites, history of primary surgery, insurance status, marital status, and income as independent prognostic factors for both OS and BCSS. CONCLUSIONS:The findings of this study provide population-based estimates of the incidence and prognosis for patients with bone metastases at initial diagnosis of breast cancer.

Dataset Information

Interval Between Cancer Diagnosis and Radiotherapy - An Independent Prognostic Factor of Survival in Patients Irradiated for Bone Metastases from Kidney Cancer.

Publications

Interval Between Cancer Diagnosis and Radiotherapy - An Independent Prognostic Factor of Survival in Patients Irradiated for Bone Metastases from Kidney Cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets